How should a pharmacy business be structured?

Who can legally own a pharmacy in the UK?

Section 69 of the Medicines Act 1968 sets the lawful routes. A retail pharmacy business can be carried on by a pharmacist as a sole trader, by a partnership, or by a body corporate that meets the superintendent conditions in section 71 of the Act. The partnership route carries a composition rule that differs by jurisdiction. In England and Wales every partner must be a pharmacist; in Scotland one or more of the partners must be.

The Act also contains representative provisions in section 72. These allow a retail pharmacy business to continue for a limited period when a pharmacist owner dies or becomes bankrupt. They matter for succession planning but not for new entrants, so this guide notes them and moves on.

Two practical readings of section 69 shape everything that follows. First, "body corporate" is broad. It covers the ordinary limited company, and it also covers the limited liability partnership (LLP), which the NHS treats as a body corporate requiring a superintendent, with LLP members treated as directors for regulatory purposes. Second, the section says nothing about who may own the body corporate. The pharmacist requirement in UK law attaches to roles, not to equity. That is the single most misunderstood point in this area, and the subject of the next section.

Where the ownership structure sits in the wider launch sequence — alongside premises, registration and the NHS decision — is mapped in how to open a distance selling pharmacy in the UK.

Can a non-pharmacist own a pharmacy?

Yes. A non-pharmacist can own a pharmacy outright through a body corporate, because the law requires pharmacists in the accountable roles, not on the share register. The shareholders of a pharmacy-owning company need not be pharmacists, and neither do its directors. There is no UK equivalent of the pharmacist-ownership restrictions found in several European markets. What the law requires instead is that the body corporate appoints a superintendent pharmacist, under whose management the professional business is carried on. A responsible pharmacist must also be in charge of each registered premises whenever it operates.

This is what makes the UK unusually open to healthcare entrepreneurs and investors entering pharmacy. It is also what concentrates so much weight on the superintendent appointment.

The commercial and professional diligence in both directions is covered in choosing and appointing a superintendent pharmacist. What the role carries day to day is covered in superintendent pharmacist responsibilities in an online pharmacy.

One boundary is worth stating plainly: ownership openness does not dilute regulation. The General Pharmaceutical Council (GPhC) assesses the company at premises registration and checks its directors. If it seeks NHS terms of service, its fitness is examined under the NHS regulations. Non-pharmacist ownership is a lawful route, not a lighter one.

What does the superintendent requirement actually mean since 2022?

Since 1 December 2022, section 71 of the Medicines Act 1968, as amended by the Pharmacy (Responsible Pharmacists, Superintendent Pharmacists etc.) Order 2022, requires the superintendent to be a pharmacist who is a senior manager of the retail pharmacy business, with authority to make decisions affecting the retail sale and supply of medicines. A written statement of the appointment, signed by both the superintendent and the body corporate, must be sent to the registrar. The same Order removed the old requirement to state whether the superintendent sits on the board. What replaced it is more demanding, not less: "senior manager with authority" is a test of substance, not a box about titles.

Two further points complete the picture. A superintendent acts for one operating body corporate at a time. The NHS England Pharmacy Manual permits acting for a second body corporate only to submit an application, not to operate pharmacies. So a structure that assumes one pharmacist can superintend several trading companies does not work. And the role is getting more codified, not less. New superintendent standards sit on the GPhC's published work programme for 2026/27, so build the role generously now rather than retrofitting it later.

What structure should you actually use?

For almost every new entrant the answer is a limited company. It combines lawful ownership by non-pharmacists, limited liability, investor compatibility and a clean home for the registration and the superintendent appointment. The alternatives exist for specific situations, not as equal defaults.

The sole trader route still suits a pharmacist opening a single pharmacy with no investment ambitions, and it removes the superintendent question entirely. But it prices that simplicity in personal liability, for a business that dispenses medicines. The England and Wales partnership rule makes traditional partnerships unusable the moment a non-pharmacist wants equity, which is most of the time. LLPs work, but they bring the superintendent requirement anyway and add the quirk that members are treated as directors for fitness purposes. In practice they offer little over a company for a trading pharmacy.

The honest summary from having structured these: incorporate a limited company and appoint the superintendent properly. Spend your sophistication on the layer above the operating company, not on exotic vehicles at the trading level.

How do holding companies and investors fit?

Holding companies sit above the operating company. The rule of thumb: everything regulatory attaches to the operating company, while everything commercial can live above it. The operating company holds the GPhC premises registration, appoints the superintendent, holds the NHS terms of service if any, employs the team and signs the leases. Shareholdings in that operating company can then be held by individuals, by founders' personal holding companies or by investor vehicles. They can be split however the shareholders' agreement provides, because the Medicines Act is silent on equity.

Three disciplines keep such structures clean, and all three come from watching them meet regulators and banks:

Trace the structure before someone else does. NHS fitness checks under the 2013 Regulations reach directors, the superintendent and LLP members. Where a director is itself a corporate body, the checks reach through to that body's own directors. Banks and payment providers run the same exercise for know-your-customer purposes, tracing to ultimate beneficial owners. A structure you cannot draw on one page, with every natural person identified, will cost you weeks somewhere. Draw it before you file anything.

Keep the registers consistent. The people with significant control (PSC) register, the director list, the shareholders' agreement and every regulatory application must tell the same story. Companies House made identity verification mandatory for directors and PSCs from November 2025, so inconsistencies surface faster than they used to. As the GPhC premises application guide puts it, reconcile the registers to the letter before filing.

Put the superintendent relationship in the shareholders' agreement. Where the superintendent is also a founder, define what happens to the role on exit, deadlock or dispute. A shareholder fight that costs the business its superintendent is a shareholder fight that suspends its right to trade. Where the superintendent is external, the appointment terms and the governance protections around their authority belong in the corporate documents, not in goodwill.

Overseas founders and investors fit through exactly the same architecture. The added questions — cross-border directorships and what transfers professionally — get their own treatment in entering the UK pharmacy market from overseas.

What checks follow the structure?

Whatever structure you choose, three sets of checks will follow it. Designing for them in advance is the difference between structure as an asset and structure as a delay. The GPhC checks the applicant entity, its directors and its superintendent at premises registration, and expects the company's records to match Companies House exactly. NHS England, for applicants seeking terms of service, applies the fitness regime of the 2013 Regulations to directors, superintendents and LLP members. That includes references for the pharmacists among them, and tracing through corporate directors to natural persons. And the commercial world — banks, payment processors, wholesalers extending credit — runs beneficial-ownership tracing that treats opacity as risk.

The pattern across all three is the same: checks attach to people, so structures should make the people easy to find. Layers added for tax, investment or succession reasons are legitimate. Layers that obscure who owns and controls a medicines business are a cost generator at best. Whether the operating company then pursues NHS terms of service or trades privately changes the contract layer but none of the ownership law — a distinction unpacked in NHS or private: what actually differs.

Key takeaways

FAQs